A clinical and histopathologic focus on barrett esophagus and barrett-related dysplasia

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 10, 2011, Pages 1249-1260

  Voltaggio, Lysandra ^a   Montgomery, Elizabeth A ^b   Lam Himlin, Dora ^c  

^a GEORGE WASHINGTON UNIVERSITY HOSPITAL   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; BARRETT ESOPHAGUS; DISEASE COURSE; ESOPHAGOSCOPY; ESOPHAGUS TUMOR; GASTROESOPHAGEAL REFLUX; HUMAN; IMMUNOHISTOCHEMISTRY; METAPLASIA; PATHOLOGY; PRECANCER; REVIEW; RISK FACTOR;

ADENOCARCINOMA; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; GASTROESOPHAGEAL REFLUX; HUMANS; IMMUNOHISTOCHEMISTRY; METAPLASIA; PRECANCEROUS CONDITIONS; RISK FACTORS;

EID: 80055077680     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0019-RA     Document Type: Review

References (73)

1. Pohl H, Sirovich B, Welch HC. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev, 2010; 19(6): 1468-1470.
2. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2008;103(3): 788-797. (Pubitemid 351406009)
3. Spechler SJ, Fitzgerald RC, Prasad GA, Wang KK. History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. Gastroenterology. 2010;138(3):854-869.
4. Playford RJ. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut. 2006;55(4):442.
5. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ; for American Gastroenterological Association. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology. 2011;140(3):1084-1091.
6. Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8(3):235-244; quiz e32.
7. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology. 2000; 119(2):333-338. (Pubitemid 30621983)
8. Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008;168(3):237-249. (Pubitemid 352019777)
9. Yachimski P, Lee RA, Tramontano A, Nishioka NS, Hur C. Secular trends in patients diagnosed with Barrett's esophagus. Dig Dis Sci. 2010;55(4):960-966.
10. Alcedo J, Ferrandez A, Arenas J, et al. Trends in Barrett's esophagus diagnosis in southern Europe: implications for surveillance. Dis Esophagus. 2009; 22(3):239-248.
11. Kaye PV, Haider SA, Ilyas M, et al. Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry. Histopathology. 2009;54(6):699-712.
12. Montgomery E, Goldblum JR, Greenson JK, et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol. 2001;32(4):379-388. (Pubitemid 32378299)
13. Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008;67(3):394-398. (Pubitemid 351260043)
14. Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol. 2000;95(12):3383-3387.
15. Lim CH, Treanor D, Dixon MF, Axon AT. Low-grade dysplasia in Barrett's esophagus has a high risk of progression. Endoscopy. 2007;39(7):581-587. (Pubitemid 47098993)
16. Spechler SJ. Barrett's esophagus. Semin Gastrointest Dis. 1996;7(2):51-60. (Pubitemid 26134943)
17. Avidan B, Sonnenberg A, Schnell TG, Sontag SJ. Hiatal hernia and acid reflux frequency predict presence and length of Barrett's esophagus. Dig Dis Sci. 2002;47(2):256-264. (Pubitemid 34123982)
18. Smith KJ, O'Brien SM, Smithers BM, et al. Interactions among smoking, obesity, and symptoms of acid reflux in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev. 2005;14(11, pt 1):2481-2486. (Pubitemid 41752705)
19. Eloubeidi MA, Provenzale D. Clinical and demographic predictors of Barrett's esophagus among patients with gastroesophageal reflux disease: a multivariate analysis in veterans. J Clin Gastroenterol. 2001;33(4):306-309. (Pubitemid 32880970)
20. Campos CM, DeMeester SR, Peters JH, et al. Predictive factors of Barrett esophagus: multivariate analysis of 502 patients with gastroesophageal reflux disease. Arch Surg. 2001;136(11):1267-1273. (Pubitemid 33043514)
21. Ward EM, Wolfsen HC, Achem SR, et al. Barrett's esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am I Gastroenterol. 2006;101(1):12-17. (Pubitemid 43381703)
22. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999,340(11):825-831. (Pubitemid 29142625)
23. Dinis-Ribeiro M, Lopes C, da Costa-Pereira A, et al. A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia. J Clin Pathol. 2004;57(2):177-182. (Pubitemid 38177758)
24. Glickman JN, Spechler SJ, Souza RF, Lunsford T, Lee E, Odze RD. Multilayered epithelium in mucosal biopsy specimens from the gastroesophageal junction region is a histologic marker of gastroesophageal reflux disease. Am J Surg Pathol. 2009;33(6):818-825.
25. Glickman JN, Chen YY, Wang HH, Antonioli DA, Odze RD. Phenotypic characteristics of a distinctive multilayered epithelium suggests that it is a precursor in the development of Barrett's esophagus. Am J Surg Pathol. 2001; 25(5):569-578. (Pubitemid 32423353)
26. Glickman JN, Yang A, Shahsafaei A, McKeon F, Odze RD. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum Pathol. 2001;32(11):1157-1165. (Pubitemid 33104425)
27. Sharma P, Weston AP, Morales T, Topalovski M, Mayo MS, Sampliner RE. Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia. Gut. 2000;46(1):9-13. (Pubitemid 30307669)
28. Weston AP, Krmpotich PT, Cherian R, Dixon A, Topalovski M. Prospective evaluation of intestinal metaplasia and dysplasia within the cardia of patients with Barrett's esophagus. Dig Dis Sci. 1997;42(3):597-602. (Pubitemid 27148348)
29. Takubo K, Aida J, Naomoto Y, et al. Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum Pathol. 2009;40(1):65-74.
30. Srivastava A, Odze RD, Lauwers GY, Redston M, Antonioli DA, Glickman JN. Morphologic features are useful in distinguishing Barrett esophagus from carditis with intestinal metaplasia. Am J Surg Pathol. 2007;31(11):1733-1741. (Pubitemid 350287572)
31. Ormsby AH, Goldblum JR, Rice TW, et al. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. Hum Pathol. 1999;30(3):288-294. (Pubitemid 29125148)
32. Ormsby AH, Vaezi MF, Richter JE, et al. Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus. Gastroenterology. 2000; 119(3):683-690.
33. van Baal JW, Bozikas A, Pronk R, et al. Cytokeratin and CDX-2 expression in Barrett's esophagus. Scand J Gastroenterol. 2008;43(2):132-140. (Pubitemid 351161518)
34. Kurtkaya-Yapicier O, Gencosmanoglu R, Avsar E, Bakirci N, Tozun N, Sav A. The utility of cytokeratins 7 and 20 (CK7/20) immunohistochemistry in the distinction of short-segment Barrett esophagus from gastric intestinal metaplasia: is it reliable? BMC Clin Pathol. 2003;3(1):5.
35. Gulmann C, Shaqaqi OA, Grace A, et al. Cytokeratin 7/20 and MUC1, 2, 5AC, and 6 expression patterns in Barrett's esophagus and intestinal metaplasia of the stomach: intestinal metaplasia of the cardia is related to Barrett's esophagus. Appl Immunohistochem Mol Morphol. 2004;12(2):142-147. (Pubitemid 38788764)
36. Sarbia M, Donner A, Franke C, Gabbert HE. Distinction between intestinal metaplasia in the cardia and in Barrett's esophagus: the role of histology and immunohistochemistry. Hum Pathol. 2004;35(3):371-376. (Pubitemid 38339613)
37. Griffel LH, Amenta PS, Das KM. Use of a novel monoclonal antibody in diagnosis of Barrett's esophagus. Dig Dis Sci. 2000;45(1):40-48. (Pubitemid 30111686)
38. Glickman JN, Shahsafaei A, Odze RD. Mucin core peptide expression can help differentiate Barrett's esophagus from intestinal metaplasia of the stomach. Am J Surg Pathol. 2003;27(10):1357-1365. (Pubitemid 37185827)
39. DeMeester SR, Wickramasinghe KS, Lord RV, et al. Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett's esophagus. Am J Gastroenterol. 2002;97(10):2514-2523.
40. El-Zimaity HM, Graham DY. Cytokeratin subsets for distinguishing Barrett's esophagus from intestinal metaplasia in the cardia using endoscopic biopsy specimens. Am J Gastroenterol. 2001 ;96(5):1378-1382. (Pubitemid 32455062)
41. Mohammed IA, Streutker CJ, Riddell RH. Utilization of cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia. Mod Pathol. 2002;15(6):611-616. (Pubitemid 34666464)
42. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001 ; 32(4):368-378. (Pubitemid 32378298)
43. Peters FP, Curvers WL, Rosmolen WD, et al. Surveillance history of endoscopically treated patients with early Barrett's neoplasia: nonadherence to the Seattle biopsy protocol leads to sampling error. Dis Esophagus. 2008;21(6): 475-479.
44. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983;14(11):931-968.
45. Appelman HD. Adenocarcinoma in Barrett mucosa treated by endoscopic mucosal resection. Arch Pathol Lab Med. 2009;133(11 ):1793-1797.
46. Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol. 1988;19(2):166-178. (Pubitemid 18091022)
47. Odze RD. Diagnosis and grading of dysplasia in Barrett's oesophagus. ; Clin Pathol. 2006;59(10):1029-1038. (Pubitemid 44570324)
48. Zhu W, Appelman HD, Greenson JK, et al. A histologically defined subset of high-grade dysplasia in Barrett mucosa is predictive of associated carcinoma. Am J Clin Pathol. 2009;132(1):94-100.
49. Abraham SC, Wang H, Wang KK, Wu TT. Paget cells in the esophagus: assessment of their histopathologic features and near-universal association with underlying esophageal adenocarcinoma. Am J Surg Pathol. 2008;32(7):1068-1074.
50. Rucker-Schmidt RL, Sanchez CA, Blount PL, et al. Nonadenomatous dysplasia in Barrett esophagus: a clinical, pathologic, and DNA content flow cytometric study. Am J Surg Pathol. 2009;33(6):886-893.
51. Mahajan D, Bennett AE, Liu X, Bena J, Bronner MP. Grading of gastric foveolar-type dysplasia in Barrett's esophagus. Mod Pathol. 2010;23(1):1-11.
52. Lomo LC, Blount PL, Sanchez CA, et al. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort. Am J Surg Pathol. 2006;30(4):423-435. (Pubitemid 43740142)
53. Zhang X, Huang Q, Goyal RK, Odze RD. DNA ploidy abnormalities in basal and superficial regions of the crypts in Barrett's esophagus and associated neoplastic lesions. Am J Surg Pathol. 2008;32(9):1327-1335.
54. Coco DP, Goldblum JR, Hornick JL, et al. Interobserver variability in the diagnosis of crypt dysplasia in Barrett esophagus. Am J Surg Pathol. 2011 ;35(1): 45-54.
55. Ormsby AH, Petras RE, Henricks WH, et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut. 2002;51(5):671-676. (Pubitemid 35216854)
56. Murray L, Sedo A, Scott M, et al. TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut. 2006;55(10):1390-1397. (Pubitemid 44476779)
57. Skacel M, Petras RE, Rybicki LA, et al. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. Am J Gastroenterol. 2002;97(10):2508-2513.
58. Sikkema M, Kerkhof M, Steyerberg EW, et al. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study. Am J Gastroenterol. 2009;104(11):2673-2680.
59. van Dekken H, Hop WC, Tilanus HW, et al. Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus. Am J Clin Pathol. 2008;130(5):745-753.
60. Dorer R, Odze RD. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. Am J Surg Pathol. 2006;30(7):871-877. (Pubitemid 44264978)
61. Sharma P. Clinical practice. Barrett's esophagus. N Engl J Med. 2009; 361(26):2548-2556.
62. Das A, Singh V, Fleischer DE, Sharma VK. A comparison of endoscopic treatment and surgery in early esophageal cancer: an analysis of surveillance epidemiology and end results data. Am J Gastroenterol. 2008;103(6):1340-1345. (Pubitemid 351813937)
63. Pohl H, Rosch T, Vieth M, et al. Miniprobe confocal laser microscopy for the detection of invisible neoplasia in patients with Barrett's oesophagus. Gut. 2008;57(12):1648-1653.
64. Meining A, Saur D, Bajbouj M, et al. In vivo histopathology for detection of gastrointestinal neoplasia with a portable, confocal miniprobe: an examiner blinded analysis. Clin Gastroenterol Hepatol. 2007;5(11):1261-1267. (Pubitemid 350019048)
65. Wallace MB, Sharma P, Lightdale C, et al. Preliminary accuracy and interobserver agreement for the detection of intraepithelial neoplasia in Barrett's esophagus with probe-based confocal laser endomicroscopy. Gastrointest Endosc. 2010;72(1):19-24.
66. Bajbouj M, Vieth M, Rosch T, et al. Probe-based confocal laser endomicroscopy compared with standard four-quadrant biopsy for evaluation of neoplasia in Barrett's esophagus. Endoscopy. 2010;42(6):435-440.
67. Kiesslich R, Gossner L, Goetz M, et al. In vivo histology of Barrett's esophagus and associated neoplasia by confocal laser endomicroscopy. Clin Gastroenterol Hepatol. 2006;4(8):979-987. (Pubitemid 44118843)
68. Lauwers GY, Forcione DG, Nishioka NS, et al. Novel endoscopic therapeutic modalities for superficial neoplasms arising in Barrett's esophagus: a primer for surgical pathologists. Mod Pathol. 2009;22(4):489-498.
69. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009;360(22):2277-2288.
70. Bronner MP, Overholt BF, Taylor SL, et al. Squamous overgrowth is not a safety concern for photodynamic therapy for Barrett's esophagus with high-grade dysplasia. Gastroenterology. 2009;136(1):56-64; quiz 351-2.
71. Fleischer DE, Odze R, Overholt BF, et al. The case for endoscopic treatment of non-dysplastic and low-grade dysplastic Barrett's esophagus. Dig Dis Sci. 2010;55(7):1918-1931.
72. Abraham SC, Krasinskas AM, Correa AM, et al. Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma. Am J Surg Pathol. 2007;31 (11 ):1719-1725. (Pubitemid 350287570)
73. Hahn HP, Shahsafaei A, Odze RD. Vascular and lymphatic properties of the superficial and deep lamina propria in Barrett esophagus. Am J Surg Pathol. 2008;32(10):1454-1461.